



CLAIMS

We Claim:


1. A method for the treatment of a *Flaviviridae* virus infection or related condition, comprising administration, to a subject in need thereof, of a therapeutically effective amount of an inhibitor of a *src* family kinase, whereby the *Flaviviridae* virus infection or related condition is diminished relative to a non-treated subject.
5
2. The method of claim 1, wherein the *Flaviviridae* virus is selected from the group consisting of a flaviviruses and hepatitis C virus (HCV).
3. The method of claim 2, wherein the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and Dengue fever virus (DEN).
10
4. The method of claim 2, wherein the *Flaviviridae* virus is hepatitis C virus (HCV).
5. The method of claim 1, wherein the *src* family kinase is c-yes kinase.
6. The method of claim 1, wherein the inhibitor comprises a *src* family kinase-specific antisense oligonucleotide.
15
7. The method of claim 6, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).
8. The method of claim 1, wherein the inhibitor comprises *src* family kinase-specific siRNA.
20
9. The method of claim 1, wherein the inhibitor comprises a small molecule inhibitor of a *src* family kinase, wherein the small molecule inhibitor is a molecule, or a pharmaceutically acceptable salt thereof, selected from the Formula group consisting of Formula I, Formula I(b), Formula II, Formula III, Formula IV and Formula V:






Formula I



I(b)



Formula II



5 wherein for Formula I or I(b), R_1 is halogen or methyl, and R_2 , R_3 and R_4 are independently a C1-C3 straight or branched alkyl; wherein for Formula II, R_1 is $-SO_2N(CH_3)_2$, or $-SO_2NH_2$; wherein for Formula III, R_2 is C_2H_5 or NHR_3 , wherein R_3 is a C1 to C3 linear or branched alkyl moiety, and wherein R_1 is independently $-(CH_2)_3N(CH_3)_2$, $-CH_2N(CH_2CH_2)_2O$, $-(CH_2)_2N(CH_2CH_2)_2O$, $-(CH_2)_3N(CH_2CH_2)_2O$, or $-(CH_2)_3N(CH_2CH_2)_2N CH_3$; and wherein for
10 Formula V, R_1 is either H or $-OCH_3$, wherein R_2 is independently $-(CH_2)_2OH$, $-CH_2COOH$, $-$

1 (CH₂)₂N(CH₃)₂, -(CH₂)₂NH(CH₂)₂OH, -(CH₂)₂NCH₃(CH₂)₂OCH₃, -(CH₂)₂N(CH₂CH₂)₂NCH₃, or -(CH₂)₂N(CH₂CH₂)₂CHOH.

10. The method of claim 9, wherein according to Formula I, the small molecule inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (“PP2”).

5 11. The method of claim 9, wherein according to Formula I(b), the small molecule inhibitor is 4-Amino-1-*tert*-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine.

12. The method of claim 9, wherein according to Formula II, the small molecule inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide.

10 13. The method of claim 9, wherein according to Formula III, R₁ is: -(CH₂)₃N(CH₃)₂; -(CH₂)₃N(CH₂CH₂)₂O; or -(CH₂)₃N(CH₂CH₂)₂NCH₃.

14. The method of claim 9, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₃)₂, wherein the small molecule inhibitor is 3-[3-(3-dimethylamino-propyl)-4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulphonic acid 15 methylamide.

15. The method of claim 9, wherein according to Formula III, R₂ is C₂H₅, and R₁ is -(CH₂)₃N(CH₃)₂.

16. The method of claim 9, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₂CH₂)₂O.

20 17. The method of claim 9, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₂CH₂)₂N CH₃.

18. The method of claim 9, wherein according to Formula III, R₂ is C₂H₅, and R₁ is -(CH₂)₃N(CH₂CH₂)₂N CH₃.

25 19. The method of claim 9, wherein according to Formula V, R₁ is -OCH₃R₂, and R₂ is -(CH₂)₂N(CH₂CH₂)₂CHOH.

20. A pharmaceutical composition having utility for the treatment of a *Flaviviridae* virus infection or related condition, comprising, along with a pharmaceutically acceptable carrier or excipient, a *src* family kinase inhibitor selected from the group consisting of: a *src* family kinase-specific antisense oligonucleotide; *src* family kinase-specific siRNA; and a small

molecule inhibitor of a *src* family kinase, wherein the small molecule inhibitor is a molecule, or a pharmaceutically acceptable salt thereof, selected from the Formula group consisting of Formula I, Formula I(b), Formula II, Formula III, Formula IV and Formula V, all according to claim 8.

5 21. The composition of claim 20, wherein the *Flaviviridae* virus is selected from the group consisting of a flaviviruses and hepatitis C virus (HCV).

22. The composition of claim 20, wherein the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and Dengue fever virus (DEN).

10 23. The composition of claim 20, wherein the *Flaviviridae* virus is hepatitis C virus (HCV).

24. The composition of claim 20, wherein the *src* family kinase is c-yes kinase.

25. The composition of claim 20, wherein according to Formula I, the small molecule inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine ("PP2").

15 26. The composition of claim 20, wherein according to Formula I(b), the small molecule inhibitor is 4-Amino-1-*tert*-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine.

27. The composition of claim 20, wherein according to Formula II, the small molecule inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide.

20 28. The composition of claim 20, wherein according to Formula III, R₁ is: -(CH₂)₃N(CH₃)₂; -(CH₂)₃N(CH₂CH₂)₂O; or -(CH₂)₃N(CH₂CH₂)₂NCH₃.

29. The composition of claim 20, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₃)₂, wherein the small molecule inhibitor is 3-[3-(3-dimethylamino-propyl)-4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulphonic acid methylamide.

25 30. The composition of claim 20, wherein according to Formula III, R₂ is C₂H₅, and R₁ is -(CH₂)₃N(CH₃)₂.

31. The composition of claim 20, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₂CH₂)₂O.

32. The composition of claim 20, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₂CH₂)₂N CH₃.

33. The composition of claim 20, wherein according to Formula III, R₂ is C₂H₅, and R₁ is -(CH₂)₃N(CH₂CH₂)₂N CH₃.

5 34. The composition of claim 20, wherein according to Formula V, R₁ is -OCH₃R₂, and R₂ is -(CH₂)₂N(CH₂CH₂)₂CHOH.

35. A method for identification of an agent having therapeutic utility for the treatment of a *Flaviviridae* virus infection or related condition, comprising:

-obtaining cells suitable to support a *Flaviviridae* virus infection;

10 -infecting the cells with the *Flaviviridae* virus;

-contacting the infected cells with an agent that inhibits a src family kinase; and

-determining whether the *Flaviviridae* virus infection is diminished, at least to some extent, relative to control infected cells not contacted by the agent, whereby the therapeutic agent is, at least in part, identified.

15 36. The method of claim 35, wherein the src family kinase is c-yes kinase.

37. The method of claim 35, wherein the *Flaviviridae* virus is selected from the group consisting of a flavivirus and hepatitis C virus (HCV).

38. The method of claim 35, wherein the flavivirus is selected from the group consisting of West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and Dengue fever virus (DEN).

39. The method of claim 35, wherein the *Flaviviridae* virus is hepatitis C virus (HCV).

40. The method of claim 35, wherein the inhibitor comprises a src family kinase-specific antisense oligonucleotide.

25 41. The method of claim 40, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

42. The method of claim 35, wherein the inhibitor comprises src family kinase-specific siRNA.

43. The method of claim 35, wherein the inhibitor comprises a small molecule

inhibitor of a *src* family kinase, wherein the small molecule inhibitor is a molecule, or a pharmaceutically acceptable salt thereof, selected from the Formula group consisting of Formula I, Formula I(b), Formula II, Formula III, Formula IV and Formula V, all according to claim 8.

44. The method of claim 35, wherein the cells suitable to support flavivirus infection

5 are selected from the group consisting of primary human hepatocellular carcinoma derived cells or cell-lines derived therefrom, Huh 7 cells, neuroblastoma cells or cell-lines derived therefrom, SKN-MC cells, and combinations thereof.

45. The method of claim 35, wherein infection precedes contacting of the cells with the agent.

10 46. The method of claim 35, wherein infection is subsequent to contacting of the cells with the agent.

47. A method for the treatment of a human immunodeficiency virus (HIV) infection or related condition, comprising administration, to a subject in need thereof, of a therapeutically effective amount of an inhibitor of a *src* family kinase, whereby the HIV infection or related 15 condition is diminished, at least to some extent, relative to a non-treated subject.


48. The method of claim 47, wherein the *src* family kinase is c-yes kinase.

49. The method of claim 47, wherein the inhibitor comprises a *src* family kinase-specific antisense oligonucleotide.


50. The method of claim 49, wherein the antisense molecule is a phosphorodiamidate 20 morpholino oligomer (PMO).

51. The method of claim 47, wherein the inhibitor comprises *src* family kinase-specific siRNA.


52. The method of claim 47, wherein the inhibitor comprises a small molecule inhibitor of a *src* family kinase, wherein the small molecule inhibitor is a molecule, or a 25 pharmaceutically acceptable salt thereof, selected from the Formula group consisting of Formula I, Formula I(b), Formula II, Formula III, Formula IV and Formula V:






Formula I



I(b)



Formula II



5 wherein for Formula I or I(b), R₁ is halogen or methyl, and R₂, R₃ and R₄ are independently a C1-C3 straight or branched alkyl; wherein for Formula II, R₁ is -SO₂N(CH₃)₂, or -SO₂NH₂; wherein for Formula III, R₂ is C₂H₅ or NHR₃, wherein R₃ is a C1 to C3 linear or branched alkyl moiety, and wherein R₁ is independently -(CH₂)₃N(CH₃)₂, -CH₂N(CH₂CH₂)₂O, -(CH₂)₂N(CH₂CH₂)₂O, -(CH₂)₃N(CH₂CH₂)₂O, or -(CH₂)₃N(CH₂CH₂)₂N CH₃; and wherein for 10 Formula V, R₁ is either H or -OCH₃, wherein R₂ is independently -(CH₂)₂OH, -CH₂COOH, -

$(\text{CH}_2)_2\text{N}(\text{CH}_3)_2$, $-(\text{CH}_2)_2\text{NH}(\text{CH}_2)_2\text{OH}$, $-(\text{CH}_2)_2\text{NCH}_3(\text{CH}_2)_2\text{OCH}_3$, $-(\text{CH}_2)_2\text{N}(\text{CH}_2\text{CH}_2)_2\text{NCH}_3$, or $-(\text{CH}_2)_2\text{N}(\text{CH}_2\text{CH}_2)_2\text{CHOH}$.

53. The method of claim 52, wherein according to Formula I, the small molecule inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-d]pyrimidine (“PP2”).

5 54. The method of claim 52, wherein according to Formula I(b), the small molecule inhibitor is 4-Amino-1-*tert*-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine.

55. The method of claim 52, wherein according to Formula II, the small molecule inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide.

10 56. The method of claim 52, wherein according to Formula III, R_1 is: - $(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$; $-(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_2)_2\text{O}$; or $-(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_2)_2\text{NCH}_3$.

15 57. The method of claim 52, wherein according to Formula III, R_2 is NH CH_3 and R_1 is $-(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$, wherein the small molecule inhibitor is 3-[3-(3-dimethylamino-propyl)-4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulphonic acid methylamide.

58. The method of claim 52, wherein according to Formula III, R_2 is C_2H_5 , and R_1 is $-(\text{CH}_2)_3\text{N}(\text{CH}_3)_2$.

59. The method of claim 52, wherein according to Formula III, R_2 is NH CH_3 and R_1 is $-(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_2)_2\text{O}$.

20 60. The method of claim 52, wherein according to Formula III, R_2 is NH CH_3 and R_1 is $-(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_2)_2\text{N CH}_3$.

61. The method of claim 52, wherein according to Formula III, R_2 is C_2H_5 , and R_1 is $-(\text{CH}_2)_3\text{N}(\text{CH}_2\text{CH}_2)_2\text{N CH}_3$.

25 62. The method of claim 52, wherein according to Formula V, R_1 is $-\text{OCH}_3\text{R}_2$, and R_2 is $-(\text{CH}_2)_2\text{N}(\text{CH}_2\text{CH}_2)_2\text{CHOH}$.

63. A pharmaceutical composition having utility for the treatment of a human immunodeficiency virus (HIV) infection or related condition, comprising, along with a pharmaceutically acceptable carrier or excipient, a *src* family kinase inhibitor selected from the group consisting of: a *src* family kinase-specific antisense oligonucleotide; *src* family kinase-

specific siRNA; and a small molecule inhibitor of a *src* family kinase, wherein the small molecule inhibitor is a molecule, or a pharmaceutically acceptable salt thereof, selected from the Formula group consisting of Formula I, Formula I(b), Formula II, Formula III, Formula IV and Formula V, all according to claim 49.

5 64. The composition of claim 63, wherein the *src* family kinase is c-yes kinase.

65. The composition of claim 63, wherein according to Formula I, the small molecule inhibitor is 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (“PP2”).

66. The composition of claim 63, wherein according to Formula I(b), the small molecule inhibitor is 4-Amino-1-*tert*-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine.

10 67. The composition of claim 63, wherein according to Formula II, the small molecule inhibitor is 2-oxo-3-(4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene)-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide.

68. The composition of claim 63, wherein according to Formula III, R₁ is: - (CH₂)₃N(CH₃)₂; -(CH₂)₃N(CH₂CH₂)₂O; or -(CH₂)₃N(CH₂CH₂)₂NCH₃.

15 69. The composition of claim 63, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₃)₂, wherein the small molecule inhibitor is 3-[3-(3-dimethylamino-propyl)-4,5,6,7-tetrahydro-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulphonic acid methylamide.

70. The composition of claim 63, wherein according to Formula III, R₂ is C₂H₅, and 20 R₁ is -(CH₂)₃N(CH₃)₂.

71. The composition of claim 63, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₂CH₂)₂O.

72. The composition of claim 63, wherein according to Formula III, R₂ is NH CH₃ and R₁ is -(CH₂)₃N(CH₂CH₂)₂N CH₃.

25 73. The composition of claim 63, wherein according to Formula III, R₂ is C₂H₅, and R₁ is -(CH₂)₃N(CH₂CH₂)₂N CH₃.

74. The composition of claim 63, wherein according to Formula V, R₁ is -OCH₃R₂, and R₂ is -(CH₂)₂N(CH₂CH₂)₂CHOH.

75. A method for identification of an agent having therapeutic utility for the

treatment of a human immunodeficiency virus (HIV) infection or related condition, comprising:

-obtaining cells suitable to support a human immunodeficiency virus (HIV) infection;

-infecting the cells with the human immunodeficiency virus (HIV);

-contacting the infected cells with an agent that inhibits a *src* family kinase; and

5 -determining whether the human immunodeficiency virus (HIV) infection is diminished relative to control infected cells not contacted by the agent, whereby the therapeutic agent is, at least in part, identified.

76. The method of claim 75, wherein the *src* family kinase is c-yes kinase.

77. The method of claim 75, wherein the inhibitor comprises a *src* family kinase-

10 specific antisense oligonucleotide.

78. The method of claim 77, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO). The method of claim 74, wherein the inhibitor comprises *src* family kinase-specific siRNA.

79. The method of claim 75, wherein the inhibitor comprises a small molecule 15 inhibitor of a *src* family kinase, wherein the small molecule inhibitor is a molecule, or a pharmaceutically acceptable salt thereof, selected from the Formula group consisting of Formula I, Formula I(b), Formula II, Formula III, Formula IV and Formula V, all according to claim 49.

80. The method of claim 75, wherein the cells suitable to support human 20 immunodeficiency virus (HIV) infection are selected from the group consisting of myeloid cells, or T-cells, and combinations thereof.

81. The method of claim 80, wherein the cells are of the myeloid cell line THP-1.

82. The method of claim 80, wherein the cells are of the T-cell leukemia cell line MT-2.

83. The method of claim 75, wherein infection precedes contacting of the cells with 25 the agent.

84. The method of claim 75, wherein infection is subsequent to contacting of the cells with the agent.

85. A method for the treatment of a human immunodeficiency virus (HIV) infection or related condition, comprising administration, to a subject in need thereof, of a therapeutically

effective amount of an inhibitor of a validated human immunodeficiency virus-induced cellular gene sequence selected from the group consisting of HMG20B, HRH1, NP, c-YES, corresponding to SEQ ID NOS:1-9, and combinations thereof, whereby the human immunodeficiency virus (HIV) infection or related condition is diminished, at least to some 5 extent, relative to a non-treated subject.

86. The method of claim 85, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of HMG20, corresponding to SEQ ID NOS:1-2.

87. The method of claim 85, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of HRH1, corresponding to SEQ ID NOS:3-5.

10 88. The method of claim 85, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of NP, corresponding to SEQ ID NOS:6-7.

89. The method of claim 85, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of c-YES, corresponding to SEQ ID NOS:8-9.

15 90. The method of claim 85, wherein the inhibitor comprises a antisense oligonucleotide specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

91. The method of claim 90, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

92. The method of claim 85, wherein the inhibitor comprises siRNA specific for the 20 respective validated human immunodeficiency virus-induced cellular gene sequence.

93. The method of claim 85, wherein the inhibitor comprises a small molecule inhibitor specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

94. A pharmaceutical composition having utility for the treatment of a human 25 immunodeficiency virus (HIV) infection or related condition, comprising, along with a pharmaceutically acceptable carrier or excipient, an inhibitor of a validated human immunodeficiency virus-induced cellular gene sequence selected from the group consisting of HMG20B, HRH1, NP, c-YES, corresponding to SEQ ID NOS:1-9, and combinations thereof, wherein the inhibitor comprises an agent selected from the group consisting of: a antisense

oligonucleotide specific for the respective validated human immunodeficiency virus-induced cellular gene sequence; siRNA specific for the respective validated human immunodeficiency virus-induced cellular gene sequence; and a small molecule inhibitor specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

5 95. The composition of claim 94, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of HMG20, corresponding to SEQ ID NOS:1-2.

96. The composition of claim 94, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of HRH1, corresponding to SEQ ID NOS:3-5.

10 97. The composition of claim 94, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of NP, corresponding to SEQ ID NOS:6-7.

98. The composition of claim 94, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of c-YES, corresponding to SEQ ID NOS:8-9.

15 99. The composition of claim 94, wherein the inhibitor comprises a antisense oligonucleotide specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

100. The composition of claim 99, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

101. The composition of claim 94, wherein the inhibitor comprises siRNA specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

20 102. The composition of claim 94, wherein the inhibitor comprises a small molecule inhibitor specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

103. A method for identification of an agent having therapeutic utility for the treatment of a human immunodeficiency virus (HIV) infection or related condition, comprising:

25 -obtaining cells suitable to support a human immunodeficiency virus (HIV) infection;

-infecting the cells with the human immunodeficiency virus (HIV);

-contacting the infected cells with an agent that inhibits a validated human immunodeficiency virus-induced cellular gene sequence selected from the group consisting of HMG20B, HRH1, NP, c-YES, corresponding to SEQ ID NOS:1-9, and combinations thereof;

and

-determining whether the human immunodeficiency virus (HIV) infection is diminished relative to control infected cells not contacted by the agent, whereby the therapeutic agent is, at least in part, identified.

5 104. The method of claim 103, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of HMG20, corresponding to SEQ ID NOS:1-2.

105. The method of claim 103, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of HRH1, corresponding to SEQ ID NOS:3-5.

106. The method of claim 103, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of NP, corresponding to SEQ ID NOS:6-7.

107. The method of claim 103, wherein the validated human immunodeficiency virus-induced cellular gene sequence is that of c-YES, corresponding to SEQ ID NOS:8-9.

108. The method of claim 103, wherein the inhibitor comprises a antisense oligonucleotide specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

109. The method of claim 108, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

110. The method of claim 103, wherein the inhibitor comprises siRNA specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

20 111. The method of claim 103, wherein the inhibitor comprises a small molecule inhibitor specific for the respective validated human immunodeficiency virus-induced cellular gene sequence.

112. The method of claim 103, wherein the cells suitable to support human immunodeficiency virus (HIV) infection are selected from the group consisting of myeloid cells, 25 or T-cells, and combinations thereof.

113. The method of claim 103, wherein the cells are of the myeloid cell line THP-1.

114. The method of claim 103, wherein the cells are of the T-cell leukemia cell line MT-2.

115. The method of claim 103, wherein infection precedes contacting of the cells with

the agent.

116. The method of claim 103, wherein infection is subsequent to contacting of the cells with the agent.